Ultragenyx Pharmaceutical Inc. (RARE) is a publicly traded Healthcare sector company. As of July 8, 2026, RARE trades at $34.57 with a market cap of $3.32B and a P/E ratio of -5.88. RARE moved -3.54% today. Year to date, RARE is +57.46%; over the trailing twelve months it is -9.44%. Its 52-week range spans $18.29 to $50.00. Analyst consensus is strong buy with an average price target of $53.79. Rallies surfaces RARE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for RARE combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $34.57 |
| Market Cap | $3.32B |
| P/E Ratio | -5.88 |
| EPS | $-6.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $50.00 |
| 52-Week Low | $18.29 |
| Volume | 1.19M |
| Avg Volume | 0 |
| Revenue (TTM) | $669.71M |
| Net Income | $-608.92M |
| Gross Margin | 0.00% |
15 analysts cover RARE: 0 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $53.79.